戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  venous thromboembolism (VTE) is how long to anticoagulate.
2 vailable radiological follow-up, and 22 were anticoagulated.
3 lent to that of patients with AF who are not anticoagulated.
4 efore stroke and 1,252 (29%) were previously anticoagulated.
5 red for alternative testing or were directly anticoagulated.
6 grade 1 or 2 thrombosis who were or were not anticoagulated.
7 /=80 and known prior AF, only 19 (9.1%) were anticoagulated.
8  focusing on periods where patients were not anticoagulated.
9                            All patients were anticoagulated.
10 he time of discharge than those who were not anticoagulated.
11 ents without specific contraindications were anticoagulated.
12                      Of the 189 patients not anticoagulated, 166 (87.8%) had no major disability prio
13 propriateness of the decision to chronically anticoagulate; 2) guide clinicians in the decision of wh
14             Three of the 4 AIS patients were anticoagulated acutely, and the nontreated patient had r
15 dosing algorithm (based on data derived from anticoagulated adults) consistently overestimated warfar
16 embolic event rates differed markedly in non-anticoagulated AF patients according to the conflicting
17                                           In anticoagulated AF patients, a validated specific bleedin
18 ation in thromboembolic event rates in a non-anticoagulated AF population, according to different gui
19 te a clear expected net clinical benefit for anticoagulating AF patients with CHA2DS2-VASc scores of
20 who lost prior allografts to thrombosis were anticoagulated after retransplantation and 100% achieved
21                                    Blood was anticoagulated alone or in combination with citrate, eth
22 ith concomitant atrial fibrillation were not anticoagulated, and 29% with arterial disease were not t
23 ts at risk for thromboembolic events are not anticoagulated, and further studies are needed to determ
24 illation at risk of stroke who are optimally anticoagulated, and reduce the burden of atrial fibrilla
25                    Subject A, who was stably anticoagulated at an INR of 2.1+/-0.4 for 6 months, had
26  the endocardial procedure, all of whom were anticoagulated at the time of the event.
27     We investigated its role on prognosis in anticoagulated atrial fibrillation (AF) patients and det
28 r disease, 65 to 74 years of age, female) in anticoagulated atrial fibrillation (AF) patients.
29  are not related to stroke in a contemporary anticoagulated atrial fibrillation population.
30 yl-L-arginine chloromethylketone and citrate-anticoagulated blood early (15 and 30 minutes) and late
31                   Meningococci were added to anticoagulated blood from 12 healthy adults vaccinated w
32                      When added to lepirudin-anticoagulated blood from healthy donors, it significant
33 elae or Bartonella elizabethae DNA from EDTA-anticoagulated blood samples obtained from four dogs was
34 de standard malariological thick smears from anticoagulated blood samples that were previously determ
35 xperimental study in which heparin- and EDTA-anticoagulated blood samples were collected from 101 HIV
36 induced platelet aggregation was measured in anticoagulated blood under static and arterial flow cond
37                                Decay in EDTA-anticoagulated blood was not significant after 6 h (bDNA
38  properties, and its superior performance in anticoagulated blood, the ECM-based hydrogel has the pot
39                                      In GPRP-anticoagulated blood, there were spontaneous elevations
40 ivation and phagocytosis of microbes in full anticoagulated blood.
41                In a cross-sectional study of anticoagulated children from 5 tertiary care centers, 12
42 ke and ABC-bleeding scores evaluated in this anticoagulated clinical trial cohort were well calibrate
43 d before the event), of whom only 14.5% were anticoagulated despite 82.3% having a CHA2DS2VASC score
44 history of stroke were more likely to remain anticoagulated despite a successful outcome from LARFA.
45  population has steadily risen where 5.9% of anticoagulated dialysis patients are started on dabigatr
46 ely((R)) recommendations include: (1) do not anticoagulate for more than 3 months in patients experie
47                        All were systemically anticoagulated for a period of 6-8 weeks after diagnosis
48                  We included 40 404 patients anticoagulated for atrial fibrillation, aged 65+, within
49 ge, 78 years; 54% male; 86% White); 81% were anticoagulated for atrial fibrillation, and the median t
50    Also, rates of major bleeding episodes in anticoagulated hemodialysis patients with AF are high.
51                  When incubated in lepirudin-anticoagulated human blood and plasma, increasing concen
52  where chicken blood clots within 30 min and anticoagulated human blood clots within 20-100 s.
53                                       Fresh, anticoagulated human blood was recirculated for 2 hours
54 on microcarrier beads and incubated with non-anticoagulated human blood were used to study binding of
55 hibited thrombosis in PPACK- but not heparin-anticoagulated human blood.
56                Leukocytes were isolated from anticoagulated human or mouse (C57BL/10J) blood using co
57                                    Lepirudin-anticoagulated human whole blood and plasma were incubat
58                                 In lepirudin-anticoagulated human whole blood, we examined the effect
59 nders spent greater proportions of time over-anticoagulated in the first 90 days of treatment (median
60 kine profile was distinct from that of fully anticoagulated, LPS-stimulated blood, which showed level
61 ls in the lung was markedly inhibited in the anticoagulated mice.
62 g antiplatelet therapy among therapeutically anticoagulated non-ST-segment-elevation myocardial infar
63                                Patients were anticoagulated orally with either adjusted-dose warfarin
64                 We recruited 965 consecutive anticoagulated outpatients with permanent or paroxysmal
65 arin compared with 21% in those who were not anticoagulated (P =.2).
66 he European tPA license precludes its use in anticoagulated patients altogether.
67 ding complications occurred in alternatively anticoagulated patients and in fondaparinux-treated pati
68 tigate predictors of bleeding in a cohort of anticoagulated patients and to evaluate the predictive v
69 fibrillation was significantly higher in non-anticoagulated patients as compared with patients receiv
70                                     Five non-anticoagulated patients experienced nonfatal thromboembo
71  data analysis from 5 prospective cohorts of anticoagulated patients following AF-associated ischemic
72 ivo studies demonstrated that platelets from anticoagulated patients had decreased VEGF release and a
73                                           In anticoagulated patients undergoing elective or semi-urge
74 mong anticoagulation-naive versus previously anticoagulated patients using multivariable Cox, Fine-Gr
75          Nine thousand five hundred eighteen anticoagulated patients were included, including 3,237 (
76                                           In anticoagulated patients with AF, bleeding was strongly a
77 e for cardiovascular events and mortality in anticoagulated patients with AF, consistent with the rel
78                                           In anticoagulated patients with AF, the C-index demonstrate
79                            In this cohort of anticoagulated patients with AF, the sole presence of di
80 sociated with important clinical outcomes in anticoagulated patients with AF.
81 with cardiovascular and bleeding outcomes in anticoagulated patients with AF.
82 ing and cardiovascular events in a cohort of anticoagulated patients with AF.
83  thrombus prevalence is high in subgroups of anticoagulated patients with AF/AFL, who may benefit fro
84  Bleeding risk represents a major concern in anticoagulated patients with atrial fibrillation (AF).
85 dicated stroke or systemic embolic events in anticoagulated patients with atrial fibrillation in the
86                                  We analyzed anticoagulated patients with atrial fibrillation who wer
87 est a different dosing in up to a quarter of anticoagulated patients with atrial fibrillation.
88 gh uncommon, should be taken into account in anticoagulated patients with Covid-19.
89 ence of allograft thrombosis was observed in anticoagulated patients with hypercoagulable states.
90  of all disabling/fatal strokes occur in non-anticoagulated patients with known prior AF.
91 /=80 years, of which 124 (33.6%) were in non-anticoagulated patients with known prior AF.
92 ommend a heparin-bridging strategy (HBS) for anticoagulated patients with moderate/high risk for thro
93  including treatment beyond 4.5 hours and in anticoagulated patients, should be explored.
94 ted in patients with Covid-19, especially in anticoagulated patients.
95 ted with nonresponse to HCC treatment in non-anticoagulated patients.
96  TUR syndrome, but requires further study in anticoagulated patients.
97                                              Anticoagulated peripheral venous blood from 19 patients
98 bility of APC to inactivate factor Va and to anticoagulate plasma.
99                These data indicate that EDTA-anticoagulated plasma is the most suitable and stable ma
100 -, heparin-, and acid citrate dextrose (ACD)-anticoagulated plasma samples were comparable.
101 nd vWF multimeric patterns in patients' EDTA-anticoagulated plasma samples.
102                 ADAMTS13 activity in citrate-anticoagulated plasma was enhanced approximately 2-fold
103 yrene surface and exposed to human lepirudin-anticoagulated plasma, the bound peptide captured factor
104                                     The EDTA-anticoagulated plasmas showed the smallest decrease in H
105 serum as well as in EDTA-, ACD-, and heparin-anticoagulated plasmas stored at -70 degrees C.
106 IV-1 RNA detected in EDTA-, heparin-, or ACD-anticoagulated plasmas.
107  of 53 nM in citrate buffer, 110 nM in PPACK anticoagulated PRP, and 4 nM in solid-phase GPIIb-IIIa c
108 mean decrease = 0.317 log units) and heparin-anticoagulated samples (mean decrease = 0.384 log units)
109 antagonists in vitro may be overestimated in anticoagulated samples of blood and best achieved in viv
110                Symptomatic patients who were anticoagulated showed a trend toward greater neurologic
111  90% of study patients when prophylactically anticoagulating study patients with hypercoagulable stat
112                                   Whether to anticoagulate such patients is controversial given the p
113 hPF4(+) animals, although these animals were anticoagulated systemically.
114 epatic, and bone marrow function; adequately anticoagulated thromboembolism; a urine protein to creat
115 02 log units) as cell-free plasma or as EDTA-anticoagulated whole blood (mean SD = +/- 0.109 log unit
116         Platelet-bound vWF in patients' EDTA-anticoagulated whole blood samples; vWF proteinase activ
117 hemoglobin (HbA1c) levels were measured from anticoagulated whole blood using an automated affinity c
118                                              Anticoagulated whole blood was added to the cartridge, a
119 article, we demonstrate that in serum and in anticoagulated whole blood, moderate concentrations of h
120 on was 50 organisms/ml of mock-infected EDTA anticoagulated whole blood.
121 ads, coated with CHC, and incubated with non-anticoagulated whole human blood.
122                   We attempted but failed to anticoagulate with warfarin.
123 assist device-supported patients are usually anticoagulated with a combination of aspirin and vitamin
124                              Groups 2-4 were anticoagulated with aspirin and Plavix, Lovenox, or Coum
125 nd to inhibit platelet aggregation in plasma anticoagulated with citrate (for ADP, mean+/-SD IC(50)=1
126 er the reduced Ca2+ concentrations in plasma anticoagulated with citrate affect Integrilin binding to
127 tin in response to ADP was greatest in blood anticoagulated with citrate compared with CTI and all ot
128 let aggregation was greater in blood samples anticoagulated with citrate versus D-phenylalanyl-L-prol
129 at platelet concentrates prepared from blood anticoagulated with citrate were unsuitable for transfus
130 re resuscitated by reinfusion of shed blood (anticoagulated with citrate-phosphate-dextrose) and crys
131                Fibrinogen was added to blood anticoagulated with corn trypsin inhibitor (a specific i
132 ess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.
133 thrombolysis, it is unclear whether patients anticoagulated with DE can be thrombolysed.
134 li and Staphylococcus aureus Human blood was anticoagulated with either GPRP or the thrombin inhibito
135 embrane oxygenation support and systemically anticoagulated with either unfractionated heparin (223 a
136 ced platelet activation was greater in blood anticoagulated with heparin compared with an equipotent
137 clotting, patients with malignancy are often anticoagulated with heparin products, which paradoxicall
138 so significantly prolonged the ACTs of blood anticoagulated with the direct thrombin inhibitors hirud
139                            All patients were anticoagulated with warfarin for > or = 3 months after L
140 clinical outcomes among patients chronically anticoagulated with warfarin or apixaban.
141 hiari syndrome (BCS) traditionally have been anticoagulated with warfarin postoperatively.
142 was also inhibited by tPA-S(481)A in WT mice anticoagulated with warfarin.

 
Page Top